All articles tagged with #rivaroxaban
A NEJM trial comparing apixaban (Eliquis) and rivaroxaban (Xarelto) found Eliquis had a lower risk of clinically relevant bleeding in patients with venous thromboembolism, with similar efficacy in preventing recurrent clots; however, results may not generalize beyond a largely white, healthy population, suggesting Eliquis could be a safer first-line option for many patients.
COBRRA (2760 patients, 3 months) shows apixaban reduces clinically relevant bleeding vs rivaroxaban in acute VTE (3.3% vs 7.1%), with major and clinically relevant nonmajor bleeding also lower (0.4% vs 2.4%; 2.9% vs 4.9%), while recurrent symptomatic VTE is similar (~1%). The safety edge could shift guidelines and insurer preference toward apixaban, though the study’s short follow-up and predominantly White population are limitations; a COBRA-AF trial in atrial fibrillation is planned.
A trial investigating the use of the anticoagulant rivaroxaban to prevent cognitive decline in atrial fibrillation (AF) patients was halted due to lack of efficacy. The BRAIN-AF study found no significant difference in cognitive decline between patients taking rivaroxaban and those on placebo, despite a high overall rate of cognitive decline. The study, which involved low-risk AF patients, suggests that other mechanisms beyond microemboli may contribute to AF-related cognitive decline, warranting further research.